FDA panel votes against inhaled mannitol for cystic fibrosis

The FDA’s deadline for making the decision on approval is in March.

FDA panelists have been cleared of potential conflicts of interest related to the topic of the meeting, although a panelist may be given a waiver, but none were granted at this meeting.

e.mechcatie@elsevier.com